Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide)

European Heart Journal

Volumn 21, Issue 3, 2000, Pages 220-229

  Klamann, A ^a   Sarfert, P ^a   Launhardt, V ^a   Schulte, G ^a   Schmiegel, W H ^a   Nauck, M A ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Ischemic preconditioning; Mortality; Myocardial infarction; Sulfonylureas; Type 2 diabetes

Indexed keywords

CREATINE KINASE; CREATINE KINASE MB; GLIBENCLAMIDE; SULFONYLUREA;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONDITIONING; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS;

AGED; CASE-CONTROL STUDIES; CREATINE KINASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GLYBURIDE; HOSPITAL MORTALITY; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MYOCARDIAL INFARCTION; SURVIVAL ANALYSIS;

EID: 0034063863     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1999.1999     Document Type: Article

References (42)

1. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 19:1970;789-730.
2. Knatterud GL, Klimt C, Osborne RK, Meinert CL, Martin DB, Hawkins NBS. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of phenformin therapy. Diabetes. 24:1975;65-187.
3. Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes. 21:1972;976-979.
4. Cornfield J. The University Group Diabetes Program. A further statistical analysis of the mortality findings. JAMA. 217:1971;1676-1687.
5. Schor S. The University Group Diabetes Program. A statistician looks at the mortality results. JAMA. 217:1971;1673-1675.
6. Ratzmann KP. Eine Analyse von alters- und geschlechtsspezifischer Diabetesprävalenz sowie Behandlungsart: Die Berlin-Studie. Akt Endokr Stoffw. 12:1991;220-223.
7. Aguilar-Bryan L, Nichols CG, Wechsler SW. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science. 268:1995;423-426.
8. +channels. Neuron. 16:1996;1011-1017.
9. Bijlstra PJ, Lutterman JA, Russel FGM, Thien T, Smits P. Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans. Diabetologia. 39:1996;1083-1090.
10. Smits P, Bijlstra PJ, Russel FG, Lutterman JA, Thien T. Cardiovascular effects of sulphonylurea derivatives. Diabetes Res Clin Pract. 31:1996;S55-9.
11. Leibowitz G, Cerasi E. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Diabetologia. 39:1996;503-514.
12. Brady PA, Terzic A. The sulfonylurea controversy: More questions from the heart. J Am Coll Cardiol. 31:1998;950-956.
13. Toombs CF, Moore TL, Shebuski RJ. Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide. Cardiovasc Res. 27:1993;617-622.
14. +channel blocker. Circulation. 90:1994;700-705.
15. ATPblockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration. Circulation. 94:1996;2297-2301.
16. Cleveland JC, Meldrum DR, Cain BS, Banerjee A, Harken AH. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium: Two paradoxes revisited. Circulation. 96:1997;29-32.
17. Cacciapuoti F, Spiezia R, Bianchi U, Lama D, Avino M, Varricchio M. Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus. Am J Cardiol. 67:1991;843-847.
18. Lomuscio A, Vergani D, Marano L, Castagnone M, Fiorentini C. Effects of glibenclamide on ventricular fibrillation in non-insulin-dependent diabetics with acute myocardial infarction. Coron Artery Dis. 5:1994;767-771.
19. Lomuscio A, Fiorentini C. Influence of oral antidiabetic treatment on electrocardiac alterations induced by myocardial infarction. Diabetes Res Clin Pract. 31:1996;S21-6.
20. Chun BY, Dobson AJ, Heller RF. The impact of diabetes on survival among patients with first myocardial infarction. Diabetes Care. 20:1997;704-708.
21. Aronson D, Rayfield EJ, Chesebro JH. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Int Med. 126:1997;296-306.
22. Miettinen H, Lehto S, Salomaa V. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care. 21:1998;69-75.
23. Rytter L, Troelsen S, Beck-Nielsen H. Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care. 8:1985;230-234.
24. Soler NG, Bennett MA, Pentecost BL, Fitzgerald MG, Malins JM. Myocardial infarction in diabetes. Q J Med. 44:1975;125-132.
25. Ulvenstam G, Aberg A, Bergstrand R. Long-term prognosis after myocardial infarction in men with diabetes. Diabetes. 34:1985;787-792.
26. N Engl J Med. 314:1986;1465-1471.
27. Anderson JL, Marshall HW, Bray BE. A randomized trial of the intracoronary streptokinase in the treatment of acute myocardial infarction. N Engl J Med. 308:1983;1312-1318.
28. Nauck MA, Sarfert P, Klamann A, Launhardt V, Schulte G, Schmiegel WH. Myocardial infarction in diabetic patients. Relation of survival in infarct size to glibenclamide therapy (abstract). Diabetes. 47:1998;A121.
29. Diabetes Care. 21:1997;S5-S22.
30. Hennekens CH, Godfried SL, Gaziano JM, Buring JE. Adjunctive drug therapy of acute myocardial infarction - evidence from clinical trials. N Engl J Med. 335:1996;1660-1667.
31. Collins R, Peto R, Baigent C, Sleight P. Aspirin, Heparin and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med. 336:1997;847-860.
32. Lehto S, Pyorala K, Miettinen H. Myocardial infarct size and mortality in patients with non-insulin-dependent diabetes mellitus. J Intern Med. 236:1994;291-297.
33. Davis TME, Parsons RW, Broadhurst R, Hobbs M, Jamrozik K. Arrythmias and mortality after myocardial infarction in diabetic patients: Relationship to diabetes treatmen (abstract). Diabetologia. 39:1996;A51.
34. Brady PA, Al-Suwaidi J, Kopeckiy SL, Terzic A. Sulfonylurea and mortality in diabetic patients with myocardial infarction. Circulation. 97:1998;709-710.
35. Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes. 29:1980;41-49.
36. Orlander PR, Goff DC, Morrissey M. The relation of diabetes to the severity of acute myocardial infarction and post-myocardial infarction survival in Mexican-Americans and non-Hispanic whites. The Corpus Christi Heart Project. Diabetes. 43:1994;897-902.
37. Woodfield SL, Lundergan CF, Reiner JS. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: The GUSTO-1 experience. J Am Coll Cardiol. 28:1996;1661-1669.
38. Lim R, Laskey W. Ischemic preconditioning in unstable coronary syndromes: Evidence for time dependence. J Am Coll Cardiol. 30:1997;1461-1465.
39. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H. Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. Cardiovasc Res. 34:1997;248-253.
40. Lancet. 352:1998;837-853.
41. Granger CB, Califf R, Young S. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. J Am Coll Cardiol. 21:1993;920-925.
42. Chambless L, Keil U, Dobson A. Population versus clinical view of case-fatality from acute coronary heart disease. Circulation. 96:1997;3849-3859.